Ivabalan

Ivabradine, the active ingredient in Ivabalan, is a If channel inhibitor presented as an oral tablet for oral use. It reduces heart rate and is employed in the management of chronic stable angina and heart failure with reduced ejection fraction in adult patients. The drug selectively inhibits the funny current in the sino‑atrial node, lowering heart rate without compromising myocardial contractility, which helps relieve angina symptoms and improve functional capacity in heart failure.

GNH USA supplies Ivabalan as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ivabradine is used to manage conditions where heart‑rate reduction is therapeutic, particularly within the cardiovascular disease spectrum. - Chronic stable angina: lowers heart rate to decrease myocardial oxygen demand and relieve chest pain. - Heart failure with reduced ejection fraction: improves left‑ventricular function and exercise capacity by controlling heart rate. - Elevated resting heart rate despite beta‑blocker therapy: provides additional rate control when beta‑blockers alone are insufficient.

Ivabradine may be associated with several adverse reactions, which are categorized by frequency.

Common Side Effects: - Bradycardia: symptomatic slowing of heart rate. - Visual disturbances (phosphenes): transient luminous phenomena. - Headache: mild to moderate intensity. - Dizziness: often related to reduced heart rate. - Fatigue: general feeling of tiredness. - Blurred vision: occasional visual acuity changes.

Serious or Rare Side Effects: - Severe bradycardia: may require medical intervention. - Atrial fibrillation: irregular heart rhythm episodes. - Symptomatic hypotension: low blood pressure causing faintness. - Heart block: impaired electrical conduction requiring monitoring.

When prescribing Ivabradine, clinicians should observe several precautionary measures to ensure safe use. - Monitor heart rate: ensure resting rate remains above the recommended minimum. - Avoid in severe hepatic impairment: reduced metabolism may increase exposure. - Caution in patients with sick sinus syndrome: risk of excessive bradycardia. - Do not combine with other strong bradycardic agents: additive effects may occur. - Avoid strong CYP3A4 inhibitors: may raise plasma concentrations. - Store below 25°C: keep in the original pack, protect from moisture.

Ivabradine can interact with other medicines, affecting its plasma concentration or additive pharmacodynamic effects.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may markedly increase ivabradine levels. - Concomitant use with other bradycardic agents (e.g., beta‑blockers, digoxin): risk of excessive heart‑rate reduction.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., erythromycin, diltiazem): may require dose adjustment. - Drugs that prolong QT interval: combined effect could increase arrhythmia risk. - Antihypertensive agents: monitor blood pressure for additive hypotensive effect.